The Viveve System is not FDA cleared for the treatment of vaginal laxity.
Investors
Viveve obtained its Series A financing from 5AM Ventures and GBS Venture Partners.
About 5AM Ventures:
Founded in 2002, 5AM Ventures makes seed and early-stage investments in next-generation life science companies, taking a focused, hands-on approach to company building. The 5AM portfolio is diversified among innovative platforms, spinouts from established biotechnology and pharmaceutical companies, and companies developing near-term products. For more information about 5AM Ventures, please visit www.5amventures.com.
About GBS Venture Partners:
GBS Venture Partners (GBS) is a leading life science venture capital firm founded in 1996. GBS invests in young businesses developing and commercializing products which, when combined with the right management and finance, will make a significant difference to patients' lives and deliver financial returns for investors. For more information about GSB, please visit www.gsbventures.com.au